Cancer Consultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.

News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Development of new cancer treatments usually begins in patients with recurrent or metastatic cancers. Once the new treatment appears effective, it is applied to earlier stages of the disease or to patients at higher risk of treatment failure.

Latest Myelodysplastic Syndrome News

Vidaza Improves Survival in High-risk Myelodysplastic Syndrome (12/11/2007) According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the agent Vidaza® (azacitidine) improves survival among patients with high-risk myelodysplastic syndrome (MDS).

Vidaza® Improves Survival in Myelodysplastic Syndromes (08/06/2007) According to a press release by Pharmion, Vidaza™ (azacitidine) significantly improves survival compared with conventional care in the treatment of myelodysplastic syndromes.

AMG 531 May Be Effective in Treating Thrombocytopenia in Patients with MDS (06/13/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), the investigative agent AMG 531 may reduce the need for platelet transfusions among patients with myelodysplastic syndromes who have thrombocytopenia.

Dacogen™ Has Significant Activity in Chronic Myelomonocytic Leukemia (02/09/2007) According to an article recently published in the journal Cancer, Dacogen™ (decitabine) provides significant anticancer activity in the treatment of chronic myelomonocytic leukemia.

Mylotarg® and Vidaza® Effective for Elderly Patients with AML or MDS (01/05/2007) Researchers from Loyola University have reported that the combination of Mylotarg® (gemtuzumab ozogamicin) and Vidaza® (azacitidine) produces a high rate of response in elderly patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The details of this study were presented at the 2006 meeting of the American Society of Hematology.

Latest Myelodysplastic Syndrome News by Stage

General

Vidaza Improves Survival in High-risk Myelodysplastic Syndrome (12/11/2007) According to results recently presented at the 2007 annual meeting of the American Society of Hematology (ASH), the agent Vidaza® (azacitidine) improves survival among patients with high-risk myelodysplastic syndrome (MDS).

Vidaza® Improves Survival in Myelodysplastic Syndromes (08/06/2007) According to a press release by Pharmion, Vidaza™ (azacitidine) significantly improves survival compared with conventional care in the treatment of myelodysplastic syndromes.

AMG 531 May Be Effective in Treating Thrombocytopenia in Patients with MDS (06/13/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), the investigative agent AMG 531 may reduce the need for platelet transfusions among patients with myelodysplastic syndromes who have thrombocytopenia.

Dacogen™ Has Significant Activity in Chronic Myelomonocytic Leukemia (02/09/2007)
According to an article recently published in the journal Cancer, Dacogen™ (decitabine) provides significant anticancer activity in the treatment of chronic myelomonocytic leukemia.